Benitec Biopharma Inc   (BNTC)
Other Ticker:  
Price: $9.2700 $0.28 3.115%
Day's High: $9.4 Week Perf: -3.94 %
Day's Low: $ 9.00 30 Day Perf: 28.57 %
Volume (M): 11 52 Wk High: $ 10.88
Volume (M$): $ 106 52 Wk Avg: $4.79
Open: $9.01 52 Wk Low: $1.86

 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Benitec Biopharma Inc
Benitec Biopharma Inc is a biotechnology company headquartered in California, USA. The company specializes in the development of gene therapy treatments for various diseases using its patented gene-silencing technology called DNA-directed RNA interference (ddRNAi). This technology allows for the suppression or elimination of specific genes associated with diseases, offering a potential cure or treatment.

Benitec Biopharma has a diverse pipeline of therapeutic candidates targeting diseases such as hepatitis B, head and neck squamous cell carcinoma, and ocular diseases. The company's lead product candidate, BB-301, is being developed as a potentially curative treatment for oculopharyngeal muscular dystrophy (OPMD), a rare genetic disease.

The company's approach focuses on creating long-lasting and potentially permanent gene expression changes, providing durable treatment options for patients. In addition to its internal pipeline, Benitec Biopharma also collaborates with research institutions and pharmaceutical companies to further develop and commercialize its gene therapy platform.

Overall, Benitec Biopharma Inc is committed to advancing the field of gene therapy and providing innovative treatments for various diseases using their proprietary ddRNAi technology.

   Company Address: 3940 Trust Way Hayward 94545 CA
   Company Phone Number: 780-0819   Stock Exchange / Ticker: NASDAQ BNTC


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Unleashing the Power of Gene Therapy BB-301 Shows Promise in OPMD TreatmentNote The title has been revised ...

Published Mon, Jul 15 2024 10:00 AM UTC

Abstract: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising results from their Phase 1b/2a clinical trial assessing the safety and efficacy of gene therapy candidate BB-301 as a potential treatment for OPMD. This art...

Benitec Biopharma Inc

Benitec Biopharma Inc Struggles to Generate Revenue in Q3 2024, What's Next for the Major Pharmaceutical Player?

In a groundbreaking development, Australian-based biopharmaceutical company Benitec Biopharma announced positive interim results from their Phase 1b/2a clinical trial for BB-301. This gene therapy holds immense potential in treating Oculopharyngeal Muscular Dystrophy (OPMD), a rare muscle disorder affecting thousands of patients worldwide. These encouraging results have the potential to significantly impact not only the lives of OPMD patients but also Benitec Biopharma's future financial performance.
Understanding OPMD and its Current Treatment Options:
Oculopharyngeal Muscular Dystrophy (OPMD) is a progressive muscle weakness disorder primarily affecting the upper eyelids and throat. This debilitating disease leads to difficulties in swallowing (dysphagia), which can result in malnutrition and aspiration pneumonia, severely impacting the quality of life for patients. Currently, treatment options for OPMD are limited to palliative care and corrective treatments, with no available disease-modifying therapies.

Clinical Study

Emerging Gene Therapy for OPMD: Encouraging Signals from Clinical Trials by Benitec Biopharma

Published Thu, Apr 18 2024 11:30 AM UTC

Australian-based Benitec Biopharma made a significant announcement indicating positive interim results from their ongoing Phase 1b/2a clinical trial for BB-301. In revolutionary strides, this gene therapy under development potentially offers hope to an estimated 15,000 Oculopharyngeal Muscular Dystrophy (OPMD) patients worldwide.OPMD is a rare, late-onset muscle disorder cha...

Management Announcement

Benitec Biopharma Inc Raises $40 Million in Oversubscribed Private Placement Financing, Fueling Groundbreaking Gene Therapy Advancements

Published Thu, Apr 18 2024 11:00 AM UTC

Rejuvenated Investor Confidence Fuels Benitec Biopharma's Successful $40 Million Private Placement Financing
HAYWARD, Calif., April 18, 2024 ? Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy, proudly announced today the successful completion of an oversubscribed private investment in public equity (PIPE) financi...

Benitec Biopharma Inc

Benitec Biopharma Inc: Pioneering Breakthroughs in the Biopharmaceutical Industry

Benitec Biopharma, a leading biotechnology company, recently announced the initiation of the first clinical trial for their gene therapy candidate, BB-301. This breakthrough marks a significant milestone in the field of gene therapy as it utilizes Benitec's innovative Silence and Replace DNA-directed RNA interference gene therapy platform. With the commencement of this trial, Benitec is paving the way for potential breakthroughs in the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic disorder.
The Genesis of a Revolutionary Approach:
Benitec's Silence and Replace DNA-directed RNA interference gene therapy platform is an innovative approach that utilizes gene silencing and gene replacement techniques. Unlike traditional treatments, this therapy aims to correct genetic abnormalities at their root cause rather than merely addressing symptoms. By specifically targeting the faulty genes responsible for OPMD, BB-301 offers a promising solution for patients suffering from this debilitating condition.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com